With Oral Agents Common, Oncology Pharmacists Are Essential in Treatment of Multiple Myeloma

SAP Partners | Health System / Oncology | <b>Yale Cancer Center</b>

With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members.

With so many approved regimens and common use of oral agents in the treatment of multiple myeloma, oncology pharmacists are essential team members, according to Terri L. Parker, MD, assistant medical director of Smilow Cancer Hospital Care Center at Yale New Haven Health.

In an interview, Parker discussed key considerations for treatment selection, safety data on the drug selinexor, the importance of facilitating collaboration between experts, and upcoming clinical trials and research that she is keeping an eye on.